Cancer Therapies
Computational Discoveries for Clinical Development of Novel Cancer Therapies
David Alvaro, Ph.D.; Anat Cohen-Dayag, Ph.D.
Pharma's Almanac
PAP-Q2-20-CL-014Jul 01, 2020
FDA
Compugen Announces FDA Clearance of IND Application for COM902
Compugen
PR-M11-19-NI-003Nov 05, 2019
Immuno-Oncology
Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium
Compugen
PR-M03-19-NI-006Mar 04, 2019
Strategic Collaboration
Compugen, MedImmune to Collaborate on Bi- and Multi-Specific Antibodies
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M04-18-NI-007Apr 12, 2018
Cell-Line
Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics
Selexis SA
PR-M03-18-NI-045Mar 13, 2018
Drug Development
Compugen Advances Lead Anti-TIGIT Monoclonal Antibody to Manufacturing
Nice Insight
PAO-M11-17-NI-025Nov 16, 2017